Composition for preventing, treating, or alleviating viral infection diseases or respiratory diseases comprising vesicle derived from lactobacillus paracasei

Abstract

Provided is a method for preventing, alleviating, or treating a viral infectious disease or a respiratory disease, comprising administering a composition containing vesicles derived from Lactobacillus paracasei as an active ingredient to a subject in need thereof, wherein the vesicles may be orally administered and delivered to the lung to suppress a respiratory disease, administered to a COVID-19 virus- or influenza virus-infected model to suppress the replication of the COVID-19 virusand clinical symptoms caused by the influenza virus.

1 . A method for alleviating or treating a viral infectious disease, the method comprising administering to a subject in need thereof a composition comprising vesicles secreted by  Lactobacillus paracasei  as an active ingredient,
 wherein the vesicles are naturally secreted from  Lactobacillus paracasei,  or isolated from a culture solution of  Lactobacillus paracasei  or food prepared by adding  Lactobacillus paracasei.      
     
     
         2 . The method of  claim 1 , wherein the viral infectious disease is any one or more viral infectious diseases selected from the group consisting of coronavirus, picornavirus, alphavirus, influenza virus, rhabdovirus, retrovirus, hepatitis B virus, hepatitis A virus, hepatitis C virus, adenovirus, herpes virus, poxvirus, parvovirus, reovirus, respiratory syncytial virus (RSV), and parainfluenza virus infectious diseases. 
     
     
         3 . The method of  claim 2 , wherein the coronavirus infectious disease is any one or more selected from the group consisting of common cold, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus infection disease-19 (COVID-19). 
     
     
         4 . The method of  claim 2 , wherein the picornavirus infectious disease is any one or more selected from the group consisting of a rhinovirus infectious disease and an enterovirus infectious disease. 
     
     
         5 . The method of  claim 2 , wherein the alphavirus infectious disease is any one or more viral infectious diseases selected from the group consisting of Barmah Forest virus, chikungunya virus, Eastern equine encephalitis virus, Mayaro virus, o'yong'yong virus, Ross River virus, Semliki Forest virus, Sindbis virus, Tonate virus, Una virus, Venezuelan equine encephalitis virus, and Western equine encephalitis virus infectious diseases. 
     
     
         6 . The method of  claim 2 , wherein the retrovirus infectious disease is any one or more viral infectious diseases selected from the group consisting of Avian leukosis virus, Rous sarcoma virus, Mouse mammary tumour virus, Murine leukemia virus, Feline leukemia virus, Bovine leukemia virus, Human T-lymphtrophic virus, and Human immunodeficiency virus (HIV) infectious diseases. 
     
     
         7 . The method of  claim 2 , wherein the herpes virus infectious disease is any one or more viral infectious diseases selected from the group consisting of Herpes simplex virus-1 (HSV-1), Herpes simplex virus-2 (HSV-2), Varicella zoster virus (VSZ), Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Roseolovirus, and Kaposi' sarcomaassociated herpesvirus (KSHV) infectious diseases. 
     
     
         8 . The method of  claim 1 , wherein the vesicles have an average diameter of 10 to 300 nm. 
     
     
         9 . The method of  claim 1 , wherein the composition is a pharmaceutical composition, a food composition, or a cosmetic composition. 
     
     
         10 . The method of  claim 1 , wherein the composition is an inhalant composition.